Christopher Brook, MD
Otolaryngology · Boston, MANPI 1326369380
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $750 of the $880 with a category attached, or 85.3%. Ambu A/s accounts for 85.3% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2024 at $750 and has fallen 91.6% since, to $63 in 2025.
Across 4 payments — averaging $219.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Ambu A/s$750
- GSK$66
- AstraZeneca$42
- Inspire Medical Systems, Inc.$21
Across 158 payments — averaging $4637.13 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$571K
- Astrazeneca UK Limited$161K
What the payments were for
- Consulting fees$75085%
- Food & beverage$13015%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Ambu A/s | 1 | $750 |
| GSK | 1 | $66 |
| AstraZeneca | 1 | $42 |
| Inspire Medical Systems, Inc. | 1 | $21 |
How this compares
$880 in reported general payments places this provider in the 55th percentile of 298 otolaryngology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 18 | $67,332 |
| Ipratropium Bromide | 191 | $5,260 |
| Azelastine Hcl | 183 | $4,651 |
| Budesonide | 12 | $2,623 |
| Fluticasone Propionate | 94 | $1,600 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 53 | $598 |
| Doxycycline Hyclate | 32 | $229 |
| Mupirocin | 18 | $148 |
| Prednisone | 23 | $60 |
Paid to pharmacies, not to this prescriber.
Other otolaryngology in Boston
- Dennis PoeBoston$264K
- Peter WeberBoston$157K
- Kevin EmerickBoston$89K
- Benjamin BleierBoston$77K
- Gregory RandolphBoston$56K
- Daniel LeeBoston$52K
- Marika RussellBoston$50K
- Isaac WassermanBoston$50K
- Phillip HuyettBoston$48K
- Thomas CarrollBoston$41K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.